Posts by Tomas G. Neilan, MD, MPH
-
Researchers Work to Reduce Heart Failure and Stroke After Radiation Therapy
The benefit of radiation and chemotherapy in treating cancer comes at the price of cardiovascular problems. Tomas G. Neilan, MD, and his team are identifying risk factors for heart problems and developing protocols to protect patients' hearts.
-
Protease inhibitors may increase risk of cardiovascular death in people with HIV and heart failure
A recent study led by Mass General researchers is the first to find that ritonavir-boosted protease inhibitor regimens increase the risk for heart failure events in persons with HIV.
-
Routine Test May help Find ICI-Related Myocarditis Early
Myocarditis related to immune checkpoint inhibitors may be identified early through EKG and Troponin tests and treated with high dose steroids
-
Cardioprotection for Cancer Patients and Survivors
Primary or secondary prevention of cardiotoxicity among patients getting treated for cancer, a call for protective measures.
Biography
Dr. Neilan received his M.D. from University College Dublin and MPH from Harvard School of Public Health. He completed internal medicine residency and cardiology training at the Mater Misericordiae Hospital in Dublin and again at Massachusetts General Hospital. He has also completed extensive training in echocardiography at Massachusetts General Hospital and cardiac magnetic resonance at the Brigham and Women's Hospital. Dr. Neilan is an Assistant Professor of Medicine at Harvard Medical School, the Director of the Cardio-Oncology Program and the Co-Director of the Cardiac MR PET CT Program.
Dr. Neilan has had a long-standing clinical and research interest in the cardiovascular care of patients with cancer. Cardiovascular disease is a leading cause of death and disability among cancer survivors and cardiovascular care for patients with cancer requires a tailored approach that is unique for each patient. He is specifically interested in how we can improve on the methods for detection of the cardiac toxicity after chemotherapy and radiotherapy and to use that information to determine how we care for patients.
